TRIZIVIR - 49702-217-18 - (abacavir sulfate, lamivudine, and zidovudine)

Alphabetical Index


Drug Information of TRIZIVIR

Product NDC: 49702-217
Proprietary Name: TRIZIVIR
Non Proprietary Name: abacavir sulfate, lamivudine, and zidovudine
Active Ingredient(s): 300; 150; 300    mg/1; mg/1; mg/1 & nbsp;   abacavir sulfate, lamivudine, and zidovudine
Administration Route(s): ORAL
Dosage Form(s): TABLET, FILM COATED
Coding System: National Drug Codes(NDC)

Labeler Information of TRIZIVIR

Product NDC: 49702-217
Labeler Name: ViiV Healthcare Company
Product Type: HUMAN PRESCRIPTION DRUG
FDA Application Number: NDA021205
Marketing Category: NDA
Start Marketing Date: 20101102

Package Information of TRIZIVIR

Package NDC: 49702-217-18
Package Description: 60 TABLET, FILM COATED in 1 BOTTLE (49702-217-18)

NDC Information of TRIZIVIR

NDC Code 49702-217-18
Proprietary Name TRIZIVIR
Package Description 60 TABLET, FILM COATED in 1 BOTTLE (49702-217-18)
Product NDC 49702-217
Product Type Name HUMAN PRESCRIPTION DRUG
Non Proprietary Name abacavir sulfate, lamivudine, and zidovudine
Dosage Form Name TABLET, FILM COATED
Route Name ORAL
Start Marketing Date 20101102
Marketing Category Name NDA
Labeler Name ViiV Healthcare Company
Substance Name ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE
Strength Number 300; 150; 300
Strength Unit mg/1; mg/1; mg/1
Pharmaceutical Classes Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA]

Complete Information of TRIZIVIR


General Information